Covance Given Consensus Recommendation of “Buy” by Analysts (NYSE:CVD)
Covance (NYSE:CVD) has been given an average recommendation of “Buy” by the fifteen ratings firms that are currently covering the company, StockRatingsNetwork.com reports. Six investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $92.96.
Covance (NYSE:CVD) opened at 83.66 on Monday. Covance has a 52 week low of $79.21 and a 52 week high of $106.50. The stock’s 50-day moving average is $85.24 and its 200-day moving average is $91.43. The company has a market cap of $4.729 billion and a price-to-earnings ratio of 30.49.
Covance (NYSE:CVD) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $0.95 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.93 by $0.02. The company had revenue of $687.10 million for the quarter, compared to the consensus estimate of $639.80 million. During the same quarter in the previous year, the company posted $0.78 earnings per share. The company’s revenue for the quarter was up 6.7% on a year-over-year basis. Analysts expect that Covance will post $3.86 EPS for the current fiscal year.
CVD has been the subject of a number of recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of Covance in a research note on Friday, August 22nd. They now have a $88.00 price target on the stock. Separately, analysts at Credit Suisse reiterated an “outperform” rating on shares of Covance in a research note on Monday, August 4th. They now have a $97.00 price target on the stock, down previously from $100.00. Finally, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Covance in a research note on Thursday, July 31st. They now have a $100.00 price target on the stock, up previously from $96.00.
Covance Inc is a drug development services company providing a range of early-stage and late-stage product development services on a worldwide basis primarily to the pharmaceutical, biotechnology and medical device industries.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.